Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat, Paclitaxel, and Radiotherapy in Stage III NSCLC
NCT00662311Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Mar 2008
- Primary completion
- Jan 2010
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in non-small cell lung cancer (NSCLC), sponsored by University of Washington. Primary endpoint: Maximum Tolerated Dose of Vorinostat at 8 weeks. Started Mar 2008; status: terminated.
02
Drugs
vorinostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00662311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00662311.